focus -WSS

focus

author：fashion 2025-09-30 00:03:45 - browse：85

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The inclusion problem at the heart of rehabilitation research

WSS

FDA sets aggressive timeline for overhauling inspection procedures

Kremlin open to talks over potential prisoner swap involving detained US reporter Evan Gershkovich

Elon Musk announces 'temporary limits' for reading Twitter posts

Future doctors need a strong humanities education

NASA releases new images of 'fingerprint

Elon Musk announces 'temporary limits' for reading Twitter posts

knowledge

focus

knowledge

Medical leaders decry Supreme Court decision on affirmative action

A pediatrician calls for Congress to pass the child tax credit deal

Wildfire smoke exposes gaps in outdoor worker protections

Dana Farber says 6 studies to be retracted and 31 corrected

As demand for Covid shots wanes, Moderna seeks its next success

There's an unseen cost to disruptive road

Supreme Court strikes down use of affirmative action

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Psychedelics group wrestles with new pharma identity

Dog Aging Project founders on what lies ahead after losing funding

Wikipedia

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

TikTok, Instagram influencers need more rules for drug ads

What causes osteoarthritis? Researchers study link to brain protein

Medicare bonuses could stop drug shortages under Senate plan

Microsoft launches AI tool for clinical documentation through Epic

Printout prescription drug information shouldn’t go digital

explore

hotspot

leisure time

knowledge